AbbVie (NYSE:ABBV) Stock Price Down 3% – Should You Sell?

AbbVie Inc. (NYSE:ABBV)’s share price was down 3% on Tuesday . The stock traded as low as $248.41 and last traded at $248.7480. Approximately 5,139,733 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 6,664,852 shares. The stock had previously closed at $256.46.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive Phase 3 LUNA results for atogepant in the prevention of menstrual migraine. The treatment met the study’s primary goal and showed efficacy and safety, potentially supporting an additional growth opportunity for the migraine portfolio. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: The LUNA data reinforces AbbVie’s position in migraine care and could expand the commercial potential of atogepant, adding another source of growth as Humira sales decline. AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results
• Positive Sentiment: HSBC raised its AbbVie price target to $315 from $300 while maintaining a Buy rating, signaling increased confidence in the company’s earnings outlook and pipeline. HSBC Adjusts Price Target on AbbVie
• Positive Sentiment: Skyrizi and Rinvoq continue to drive immunology growth, while new indications, partnerships and acquisitions—including the Apogee Therapeutics transaction—are intended to build AbbVie’s next wave of products. AbbVie’s Immunology Franchise
• Positive Sentiment: AbbVie declared a quarterly cash dividend of $1.73 per share, supporting the stock’s income appeal and indicating continued confidence in cash generation. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Analyst commentary highlights AbbVie’s successful transition away from Humira toward newer immunology products, but also raises questions about whether future growth is becoming too dependent on Skyrizi and Rinvoq. AbbVie vs. Novo Nordisk
• Negative Sentiment: The FDA issued a complete response letter for the fast-acting neurotoxin trenibotE, delaying or complicating a potential product launch and adding regulatory risk to AbbVie’s aesthetics pipeline. FDA Issues Complete Response Letter for TrenibotE

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ABBV shares. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Barclays raised their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Cantor Fitzgerald lifted their target price on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Canaccord Genuity Group increased their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, BMO Capital Markets raised their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $276.64.

AbbVie Price Performance

The firm has a market capitalization of $450.52 billion, a price-to-earnings ratio of 72.03, a PEG ratio of 1.13 and a beta of 0.29. The firm has a 50 day moving average price of $254.66 and a 200-day moving average price of $230.55.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AbbVie

Large investors have recently modified their holdings of the company. California State Teachers Retirement System raised its stake in AbbVie by 25,250.3% in the second quarter. California State Teachers Retirement System now owns 679,435,549 shares of the company’s stock valued at $170,973,162,000 after buying an additional 676,755,361 shares in the last quarter. State Street Corp raised its position in shares of AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC increased its stake in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE increased its stake in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Finally, Norges Bank acquired a new stake in AbbVie during the fourth quarter worth approximately $5,865,055,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.